EUSA Pharma (UK) Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 300

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 9

  • Investments
  • 5

EUSA Pharma (UK) General Information

Description

Operator of a specialty pharmaceutical company specializing in oncology and other critical diseases. The company offers biopharmaceutical products focused on rare diseases, for the treatment of oral mucositis, a common and debilitating side-effect of radiotherapy and high-dose chemotherapy, thereby enabling patients to cure their problems with effective treatment.

Contact Information

Formerly Known As
Essex Bidco
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly PE-Backed
Corporate Office
  • Breakspear Park
  • Breakspear Way
  • Hemel Hempstead HP2 4TZ
  • England, United Kingdom
Primary Industry
Pharmaceuticals
Parent Company
Vertical(s)
Corporate Office
  • Breakspear Park
  • Breakspear Way
  • Hemel Hempstead HP2 4TZ
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EUSA Pharma (UK) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore EUSA Pharma (UK)‘s full profile, request access.

Request a free trial

EUSA Pharma (UK) Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a specialty pharmaceutical company specializing in oncology and other critical diseases. The company offers
Pharmaceuticals
Hemel Hempstead, United Kingdom
300 As of 2024

Cambridge, United Kingdom
 

Newton, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

EUSA Pharma (UK) Competitors (8)

One of EUSA Pharma (UK)’s 8 competitors is Astex Pharmaceuticals, a Corporate Backed or Acquired company based in Cambridge, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Astex Pharmaceuticals Corporate Backed or Acquired Cambridge, United Kingdom
Karyopharm Therapeutics Formerly VC-backed Newton, MA
Amryt Pharma Corporate Backed or Acquired London, United Kingdom
Verona Pharma Corporate Backed or Acquired London, United Kingdom
Veru Corporation Miami, FL
You’re viewing 5 of 8 competitors. Get the full list »

EUSA Pharma (UK) Patents

EUSA Pharma (UK) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2008151226-A1 Treatment of vertebral cancer with 153 samarium Inactive 04-Jun-2007
WO-2008153802-A1 Ex-vivo treatment of cancer using psma and antibodies thereto Inactive 29-May-2007

EUSA Pharma (UK) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EUSA Pharma (UK) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore EUSA Pharma (UK)‘s full profile, request access.

Request a free trial

EUSA Pharma (UK) Investments (5)

EUSA Pharma (UK)’s most recent deal was a Buyout/LBO with Sylvant for . The deal was made on 01-Jul-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Sylvant 01-Jul-2018 Buyout/LBO Buildings and Property
Apeiron Biologics (dinutuximab beta) 04-Oct-2016 Buyout/LBO Buildings and Property
Arcoral Pharma (Arcoral Tab) 12-Apr-2016 Corporate Asset Purchase Buildings and Property
Cytogen 08-May-2008 Buyout/LBO Pharmaceuticals
OPi 22-Mar-2007 Buyout/LBO Biotechnology
To view EUSA Pharma (UK)’s complete investments history, request access »

EUSA Pharma (UK) Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Eusa Pharma (Denmark) Hellerup, Denmark 2017
Recordati Netherlands Schipholrijk, Netherlands 2015

EUSA Pharma (UK) FAQs

  • When was EUSA Pharma (UK) founded?

    EUSA Pharma (UK) was founded in 2006.

  • Where is EUSA Pharma (UK) headquartered?

    EUSA Pharma (UK) is headquartered in Hemel Hempstead, United Kingdom.

  • What is the size of EUSA Pharma (UK)?

    EUSA Pharma (UK) has 300 total employees.

  • What industry is EUSA Pharma (UK) in?

    EUSA Pharma (UK)’s primary industry is Pharmaceuticals.

  • Is EUSA Pharma (UK) a private or public company?

    EUSA Pharma (UK) is a Private company.

  • What is the current valuation of EUSA Pharma (UK)?

    The current valuation of EUSA Pharma (UK) is .

  • What is EUSA Pharma (UK)’s current revenue?

    The current revenue for EUSA Pharma (UK) is .

  • How much funding has EUSA Pharma (UK) raised over time?

    EUSA Pharma (UK) has raised $151M.

  • Who are EUSA Pharma (UK)’s investors?

    3i Group, Advent Life Sciences, Advent Venture Partners, Alexandra Investment Management, and Alpha Leonis Partners are 5 of 22 investors who have invested in EUSA Pharma (UK).

  • Who are EUSA Pharma (UK)’s competitors?

    Astex Pharmaceuticals, Karyopharm Therapeutics, Amryt Pharma, Verona Pharma, and Veru are some of the 8 competitors of EUSA Pharma (UK).

  • When was EUSA Pharma (UK) acquired?

    EUSA Pharma (UK) was acquired on 16-Mar-2022.

  • Who acquired EUSA Pharma (UK)?

    EUSA Pharma (UK) was acquired by Recordati.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process